-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sozinibercept in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sozinibercept in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Sozinibercept in Wet (Neovascular / Exudative) Macular Degeneration Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – REC-2282 in Neurofibromatoses Type II
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - REC-2282 in Neurofibromatoses Type II report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.REC-2282 in Neurofibromatoses Type IIDrug Details:REC-2282 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ORIC-533 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORIC-533 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ORIC-533 in Relapsed Multiple MyelomaDrug Details:ORIC-533 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ORIC-533 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORIC-533 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ORIC-533 in Refractory Multiple MyelomaDrug Details:ORIC-533 is under development for the treatment...
-
Company Insights
Innovation and Patenting activity of ORIC Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of ORIC Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Profile
ORIC Pharmaceuticals Inc – Company Profile
ORIC Pharmaceuticals Inc (ORIC) is a clinical-stage pharmaceutical company. It focuses on therapies to treat cancer. The company’s pipeline product pipeline includes ORIC-533, a orally bioavailable small molecule inhibitor for treatment of multiple myeloma; ORIC-114 to treat non-small cell lung cancer and breast and tumor agnostic; and ORIC-944 to treat prostate cancer. It is also developing multiple drug programs for therapeutic areas of breast cancer, and solid tumors. ORIC is headquartered in South San Francisco, California, the US.
Add to Basket -
Product Insights
Multiple Myeloma (Kahler Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Myeloma Pipeline Products Market Report Overview Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. It mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain, and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery. The Multiple Myeloma Drugs in Development market research...
-
Product Insights
Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Prostate cancer usually occurs in older men. Its symptoms include problems while urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips, or thighs, bone pain, and erectile dysfunction. The Prostate Cancer pipeline market research report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the...
-
Product Insights
Net Present Value Model: ORIC-114
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model ORIC-114 Drug Details VRN-07 is under...